Nephrol Dial Transplant (2000) 15: 1425-1430
© 2000 European Renal Association-European Dialysis and Transplant Association
Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure
1 Departments of Nephrology and 3 Cardiology, The Royal Melbourne Hospital, Melbourne, Victoria, and 2 Department of Physiology, University of Melbourne, Melbourne, Victoria, Australia
Background. The optimal haemoglobin concentration ([Hb]) for patients with end-stage renal failure is uncertain. In particular, it is unclear whether Hb normalization may be an advantage to such patients who are otherwise well.
Methods. A prospective, randomized, double-blind cross-over study was completed in 14 haemodialysis patients (12 male) aged between 23 and 65 years over a period of 18 months, using a variety of measures to examine the effect of epoetin at target [Hb] of 10 g/dl ([Hb]10) and 14 g/dl ([Hb]14). Patients were randomized to maintain one or other of the target levels for 6 weeks before being crossed over to the alternative [Hb]. Baseline data (mean [Hb]: 8.5±0.2 g/dl) were also included selectively. Six patients were known to be hypertensive. Comparisons were made between 24-h ambulatory blood pressure levels (ABP), echocardiographic findings and estimates of blood volume (BV), plasma volume (PV) and Hb mass. Quality of life estimates were obtained using the Sickness Impact Profile (SIP), and epoetin dosage requirements at target [Hb] were assessed.
Results. Daytime and nocturnal ABP (systolic and diastolic) were not different at the respective target [Hb], although nocturnal diastolic levels were higher compared with baseline (73±4 mmHg) at both [Hb]10 (83±3, P<0.01) and [Hb]14 (81±6, P<0.05). Significant reductions in cardiac output (5.2±0.3 vs 6.6±0.5 l/min, P<0.01) and left ventricular end-diastolic diameter (4.8±0.2 vs 5.2±0.2 cm, P<0.001) were found at [Hb]14 compared with [Hb]10. Left ventricular mass index was correlated with both PV (P<0.001) and BV (P<0.01), but not with Hb mass. The PV decreased as the [Hb] rose (P<0.001) but BV remained unchanged. Quality of life was significantly improved at [Hb]14 compared with [Hb]10 for both total score (6.5±1.7 vs 13.4±3.0, P=0.01) and psychosocial dimension score (5.4±1.9 vs 15.4±4.0, P<0.01). The maintenance weekly dose of epoetin required was 80% higher at [Hb]14 compared with [Hb]10 (P<0.001).
Conclusion. These data suggest there may be a significant haemodynamic and symptomatic advantage in maintaining a physiological [Hb] in haemodialysis patients. Although untoward effects were not identified in this study at [Hb]14, a substantially higher dose of epoetin is required to maintain this level.
Keywords: blood pressure and volume; epoetin dosage; haemodialysis; haemoglobin; quality of life
Correspondence and offprint requests to: L. P. McMahon, Department of Nephrology, The Royal Melbourne Hospital, Melbourne, Victoria, 3050, Australia.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. van der Meer and D. J van Veldhuisen Anaemia and renal dysfunction in chronic heart failure Heart, November 1, 2009; 95(21): 1808 - 1812. [Full Text] [PDF]
|
|
|
|
 |
|
 I. S. Anand Anemia and Chronic Heart Failure: Implications and Treatment Options J. Am. Coll. Cardiol., August 12, 2008; 52(7): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. P. Conlon, E. P. Bale, G. P. Herbison, and M. McCarroll Postoperative Anemia and Quality of Life After Primary Hip Arthroplasty in Patients Over 65 Years Old Anesth. Analg., April 1, 2008; 106(4): 1056 - 1061. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. E Murray-Kolb and J. L Beard Iron treatment normalizes cognitive functioning in young women Am. J. Clinical Nutrition, March 1, 2007; 85(3): 778 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. C. Macdougall, R. M. Temple, J. T. C. Kwan, and on behalf of the EPO-GBR-2 Study Group Is early treatment of anaemia with epoetin-{alpha} beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial Nephrol. Dial. Transplant., March 1, 2007; 22(3): 784 - 793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Rossert, C. Gassmann-Mayer, D. Frei, and W. McClellan Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients Nephrol. Dial. Transplant., March 1, 2007; 22(3): 794 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Roger and A. Levin Epoetin trials: randomised controlled trials don't always mimic observational data Nephrol. Dial. Transplant., March 1, 2007; 22(3): 684 - 686. [Full Text] [PDF]
|
|
|
|
|
|
A. Levin Understanding recent haemoglobin trials in CKD: methods and lesson learned from CREATE and CHOIR Nephrol. Dial. Transplant., February 1, 2007; 22(2): 309 - 312. [Full Text] [PDF]
|
|
|
|
|
|
E. Lipsic, R. G. Schoemaker, P. van der Meer, A. A. Voors, D. J. van Veldhuisen, and W. H. van Gilst Protective Effects of Erythropoietin in Cardiac Ischemia: From Bench to Bedside J. Am. Coll. Cardiol., December 5, 2006; 48(11): 2161 - 2167. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. B. Drueke, F. Locatelli, N. Clyne, K.-U. Eckardt, I. C. Macdougall, D. Tsakiris, H.-U. Burger, A. Scherhag, and the CREATE Investigators Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia N. Engl. J. Med., November 16, 2006; 355(20): 2071 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Regidor, J. D. Kopple, C. P. Kovesdy, R. D. Kilpatrick, C. J. McAllister, J. Aronovitz, S. Greenland, and K. Kalantar-Zadeh Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1181 - 1191. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Paoletti and G. Cannella Update on Erythropoietin Treatment: Should Hemoglobin Be Normalized in Patients with Chronic Kidney Disease? J. Am. Soc. Nephrol., April 1, 2006; 17(4_suppl_2): S74 - S77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Levin, O. Djurdjev, J. Duncan, D. Rosenbaum, and R. Werb Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes Nephrol. Dial. Transplant., February 1, 2006; 21(2): 370 - 377. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. S. Parfrey, R. N. Foley, B. H. Wittreich, D. J. Sullivan, M. J. Zagari, D. Frei, and for the Canadian European Study Double-Blind Comparison of Full and Partial Anemia Correction in Incident Hemodialysis Patients without Symptomatic Heart Disease J. Am. Soc. Nephrol., July 1, 2005; 16(7): 2180 - 2189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Tolman, D. Richardson, C. Bartlett, and E. Will Structured Conversion from Thrice Weekly to Weekly Erythropoietic Regimens Using a Computerized Decision-Support System: A Randomized Clinical Study J. Am. Soc. Nephrol., May 1, 2005; 16(5): 1463 - 1470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. F.M. Strippoli, J. C. Craig, C. Manno, and F. P. Schena Hemoglobin Targets for the Anemia of Chronic Kidney Disease: A Meta-analysis of Randomized, Controlled Trials J. Am. Soc. Nephrol., December 1, 2004; 15(12): 3154 - 3165. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. van der Meer, A. A. Voors, E. Lipsic, W. H. van Gilst, and D. J. van Veldhuisen Erythropoietin in cardiovascular diseases Eur. Heart J., February 2, 2004; 25(4): 285 - 291. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Roger, L. P. McMahon, A. Clarkson, A. Disney, D. Harris, C. Hawley, H. Healy, P. Kerr, K. Lynn, A. Parnham, et al. Effects of Early and Late Intervention with Epoetin {alpha} on Left Ventricular Mass among Patients with Chronic Kidney Disease (Stage 3 or 4): Results of a Randomized Clinical Trial J. Am. Soc. Nephrol., January 1, 2004; 15(1): 148 - 156. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Snyder, R. N. Foley, D. T. Gilbertson, E. F. Vonesh, and A. J. Collins Hemoglobin Levels and Erythropoietin Doses in Hemodialysis and Peritoneal Dialysis Patients in the United States J. Am. Soc. Nephrol., January 1, 2004; 15(1): 174 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Minutolo, L. D. Nicola, V. Bellizzi, C. Iodice, R. Rubino, F. Aucella, C. Stallone, F. Nappi, F. Avella, E. Maione, et al. Intra- and post-dialytic changes of haemoglobin concentrations in non-anaemic haemodialysis patients Nephrol. Dial. Transplant., December 1, 2003; 18(12): 2606 - 2612. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. C. Macdougall CREATE: new strategies for early anaemia management in renal insufficiency Nephrol. Dial. Transplant., June 1, 2003; 18(suppl_2): ii13 - ii16. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Furuland, T. Linde, J. Ahlmen, A. Christensson, U. Strombom, and B. G. Danielson A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients Nephrol. Dial. Transplant., February 1, 2003; 18(2): 353 - 361. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. O'Riordan and R. N. Foley When should we start erythropoietin therapy? Nephrol. Dial. Transplant., May 1, 2001; 16(5): 891 - 892. [Full Text] [PDF]
|
|